ClinVar Miner

Submissions for variant NM_007294.3(BRCA1):c.1082_1092del (p.Cys360_Ser361insTer) (rs80359880)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000077481 SCV000299536 pathogenic Breast-ovarian cancer, familial 1 2016-09-08 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
Ambry Genetics RCV000165309 SCV000216031 pathogenic Hereditary cancer-predisposing syndrome 2018-03-21 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Alterations resulting in premature truncation (e.g.reading frame shift, nonsense)
Michigan Medical Genetics Laboratories,University of Michigan RCV000077481 SCV000267689 pathogenic Breast-ovarian cancer, familial 1 2016-04-21 criteria provided, single submitter clinical testing
GeneDx RCV000254901 SCV000322183 pathogenic not provided 2018-03-06 criteria provided, single submitter clinical testing This deletion of 11 nucleotides is denoted BRCA1 c.1082_1092del11 at the cDNA level and p.Ser361Ter (S361X) at the protein level. The normal sequence, with the bases that are deleted in braces, is TGCT[del11]AGAG. The substitution creates a nonsense variant, which changes a Serine to a premature stop codon (TCA>TAG). This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. BRCA1 c.1082_1092del11, previously reported as 1201del11, has been reported in several kindreds with early-onset breast and/or ovarian cancer diagnoses and is thought to be a founder variant in the Swedish population (Shattuck-Eidens 1995, Johannsson 1996, Loman 2001, Malander 2004, Borg 2010). We consider this variant to be pathogenic.
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge RCV000077481 SCV000324948 pathogenic Breast-ovarian cancer, familial 1 2015-10-02 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000507754 SCV000602678 pathogenic not specified 2016-09-12 criteria provided, single submitter clinical testing
Counsyl RCV000077481 SCV000785418 pathogenic Breast-ovarian cancer, familial 1 2017-07-27 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000254901 SCV000888831 pathogenic not provided 2017-12-11 criteria provided, single submitter clinical testing
Color RCV000165309 SCV000904685 pathogenic Hereditary cancer-predisposing syndrome 2015-02-17 criteria provided, single submitter clinical testing
Sharing Clinical Reports Project (SCRP) RCV000077481 SCV000109279 pathogenic Breast-ovarian cancer, familial 1 2012-08-14 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000077481 SCV000144001 pathogenic Breast-ovarian cancer, familial 1 2013-02-20 no assertion criteria provided clinical testing
Research Molecular Genetics Laboratory,Women's College Hospital, University of Toronto RCV000496348 SCV000587100 pathogenic Hereditary breast and ovarian cancer syndrome 2014-01-31 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.